Imidaprilat inhibits matrix metalloproteinase-2 activity in human cardiac fibroblasts induced by interleukin-1β via NO-dependent pathway

International Journal of Cardiology

Volumn 126, Issue 3, 2008, Pages 414-420

  Guo, Xiao Gang ^a,b   Uzui, Hiroyasu ^b   Mizuguchi, Toshihiro ^b   Ueda, Takanori ^b   Chen, Jun zhu ^a   Lee, Jong Dae ^b  

^a ZHEJIANG UNIVERSITY   (China)

^b Faculty of Medical Sciences   (Japan)

Author keywords

Angiotensin converting enzyme inhibitors; Cardiac fibroblasts; Inflammatory cytokine; Matrix metalloproteinases; Nitrix oxide

Indexed keywords

BETA1 INTERFERON; GELATINASE A; IMIDAPRILAT; N(G) METHYLARGININE; NITRIC OXIDE; NITROPRUSSIDE SODIUM; TISSUE INHIBITOR OF METALLOPROTEINASE 2;

ARTICLE; CONTROLLED STUDY; DRUG ANTAGONISM; DRUG EFFECT; DRUG INHIBITION; ENZYME ACTIVITY; ENZYME INHIBITION; FIBROBLAST; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SINGLE NUCLEOTIDE POLYMORPHISM; ZYMOGRAPHY;

ANALYSIS OF VARIANCE; CELLS, CULTURED; ELECTROPHORESIS, POLYACRYLAMIDE GEL; FIBROBLASTS; HUMANS; IMIDAZOLIDINES; INTERLEUKIN-1BETA; MATRIX METALLOPROTEINASE 2; MYOCYTES, CARDIAC; NITRIC OXIDE; PROBABILITY; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RISK FACTORS; RNA; SENSITIVITY AND SPECIFICITY; SIGNAL TRANSDUCTION;

EID: 43049159105     PISSN: 01675273     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijcard.2007.08.134     Document Type: Article

References (38)

1. Spinale F.G. Matrix metalloproteinases: regulation and dysregulation in the failing heart. Circ Res 90 (2002) 520-530
2. Benjamin I.J. Matrix metalloproteinases: from biology to therapeutic strategies in cardiovascular disease. J Investig Med 49 (2001) 381-397
3. Tsuruda T., Costello-Boerrigter L.C., and Burnett Jr. J.C. Matrix metalloproteinases: pathways of induction by bioactive molecules. Heart Fail Rev 9 (2004) 53-61
4. Gomez D.E., Alonso D.F., Yoshiji H., and Thorgeirsson U.P. Tissue inhibitors of metalloproteinases: structure, regulation and biological functions. Eur J Cell Biol 74 (1997) 111-122
5. Li Z., Li L., Zielke H.R., et al. Increased expression of 72-kd type IV collagenase (MMP-2) in human aortic atherosclerotic lesions. Am J Pathol 148 (1996) 121-128
6. Patterson M.L., Atkinson S.J., Knãuper V., and Murphy G. Specific collagenolysis by gelatinase A, MMP-2, is determined by the hemopexin domain and not the fibronectin-like domain. FEBS Lett 503 (2001) 158-162
7. Lee R.T. Matrix metalloproteinase inhibition and the prevention of heart failure. Trends Cardiovasc Med 11 (2001) 202-205
8. Hayashidani S., Tsutsui H., Ikeuchi M., et al. Targeted deletion of MMP-2 attenuates early LV rupture and late remodeling after experimental myocardial infarction. Am J Physiol Heart Circ Physiol 285 (2003) H1229-H1235
9. Matsusaka H., Ide T., Matsushima S., et al. Targeted deletion of matrix metalloproteinase 2 ameliorates myocardial remodeling in mice with chronic pressure overload. Hypertension 47 (2006) 711-717
10. Dagenais G.R., Pogue J., Fox K., Simoons M.L., and Yusuf S. Angiotensin-converting-enzyme inhibitors in stable vascular disease without left ventricular systolic dysfunction or heart failure: a combined analysis of three trials. Lancet 368 (2006) 581-588
11. Schieffer B., and Drexler H. Role of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors, angiotensin-converting enzyme inhibitors, cyclooxygenase-2 inhibitors, and aspirin in anti-inflammatory and immunomodulatory treatment of cardiovascular diseases. Am J Cardiol 91 (2003) 12H-18H
12. Stanisavljevic S., Ignjatovic T., Deddish P.A., et al. Angiotensin I-converting enzyme inhibitors block protein kinase C epsilon by activating bradykinin B1 receptors in human endothelial cells. J Pharmacol Exp Ther 316 (2006) 1153-1158
13. Sakata Y., Yamamoto K., Mano T., et al. Activation of matrix metalloproteinases precedes left ventricular remodeling in hypertensive heart failure rats: its inhibition as a primary effect of Angiotensin-converting enzyme inhibitor. Circulation 109 (2004) 2143-2149
14. Eghbali M., Czaja M.J., Zeydel M., et al. Collagen chain mRNAs in isolated heart cells from young and adult rats. J Mol Cell Cardiol 20 (1988) 267-276
15. Eghbali M., Blumenfeld O.O., Seifter S., et al. Localization of types I, III and IV collagen mRNAs in rat heart cells by in situ hybridization. J Mol Cell Cardiol 21 (1989) 103-113
16. Cleutjens J.P., Kandala J.C., Guarda E., Guntaka R.V., and Weber K.T. Regulation of collagen degradation in the rat myocardium after infarction. J Mol Cell Cardiol 27 (1995) 1281-1292
17. Xie Z., Singh M., and Singh K. Differential regulation of matrix metalloproteinase-2 and -9 expression and activity in adult rat cardiac fibroblasts in response to interleukin-1beta. J Biol Chem 279 (2004) 39513-39519
18. Cucoranu I., Clempus R., Dikalova A., et al. NAD(P)H oxidase 4 mediates transforming growth factor-beta1-induced differentiation of cardiac fibroblasts into myofibroblasts. Circ Res 97 (2005) 900-907
19. Uzui H., Lee J.D., Shimizu H., Tsutani H., and Ueda T. The role of protein-tyrosine phosphorylation and gelatinase production in the migration and proliferation of smooth muscle cells. Atherosclerosis 149 (2000) 51-59
20. Uzui H., Harpf A., Liu M., et al. Increased expression of membrane type 3-matrix metalloproteinase in human atherosclerotic plaque: role of activated macrophages and inflammatory cytokines. Circulation 106 (2002) 3024-3030
21. Green L., Wagner D., Glogowski J., et al. Analysis of nitrate, nitrite, and (15N)nitrate in biological fluids. Anal Biochem. 126 (1982) 131-138
22. Adamopoulos S., Parissis J.T., and Kremastinos D.T. A glossary of circulating cytokines in chronic heart failure. Eur J Heart Fail 3 (2001) 517-526
23. Aukrust P., Ueland T., Lien E., et al. Cytokine network in congestive heart failure secondary to ischemic or idiopathic dilated cardiomyopathy. Am J Cardiol 83 (1999) 376-382
24. Aukrust P., Ueland T., Müller F., et al. Elevated circulating levels of C-C chemokines in patients with congestive heart failure. Circulation 97 (1998) 1136-1143
25. Damås J.K., Gullestad L., Ueland T., et al. CXC-chemokines, a new group of cytokines in congestive heart failure-possible role of platelets and monocytes. Cardiovasc Res 45 (2000) 428-436
26. Deten A., Volz H.C., Briest W., and Zimmer H.G. Cardiac cytokine expression is upregulated in the acute phase after myocardial infarction. Experimental studies in rats. Cardiovasc Res 55 (2002) 329-340
27. Irwin M., Mak S., Mann D., et al. Tissue expression and immunolocalization of tumour necrosis factor-alpha in post infarction-dysfunctional myocardium. Circulation 99 (1999) 1492-1498
28. Galis Z.S., Muszynski M., Sukhova G.K., Simon-Morrissey E., and Libby P. Enhanced expression of vascular matrix metalloproteinases induced in vitro by cytokines and in regions of human atherosclerotic lesions. Ann NY Acad Sci 748 (1995) 501-507
29. Birks E.J., Yacoub M.H., Burton P.S., et al. Activation of apoptotic and inflammatory pathways in dysfunctional donor hearts. Transplantation 70 (2000) 1498-1506
30. Reinhardt D., Sigusch H.H., Henbe J., et al. Cardiac remodeling in end stage heart failure: upregulation of matrix metalloproteinase (MMP) irrespective of the underlying disease, and evidence for a direct inhibitory effect of ACE inhibitors on MMP. Heart 88 (2002) 525-530
31. Seeland U., Kouchi I., Zolk O., Itter G., Linz W., and Bohm M. Effect of ramipril and furosemide treatment on interstitial remodeling in post-infarction heart failure rat hearts. J Mol Cell Cardiol 34 (2002) 151-163
32. Murphy M. Nitric oxide and cell death. Biochim Biophys Acta 1411 (1999) 401-414
33. Tian B., Liu J., Bitterman P., and Bache R.J. Angiotensin II modulates nitric oxide-induced cardiac fibroblast apoptosis by activation of AKT/PKB. Am J Physiol Heart Circ Physiol 285 (2003) H1105-H1112
34. Balligand J.L., and Cannon P.J. Nitric oxide synthases and cardiac muscle. Autocrine and paracrine influences. Arterioscler Thromb Vasc Biol 17 (1997) 1846-1858
35. Joe E.K., Schussheim A.E., Longrois D., et al. Regulation of cardiac myocyte contractile function by inducible nitric oxide synthase (iNOS): mechanisms of contractile depression by nitric oxide. J Mol Cell Cardiol 30 (1998) 303-315
36. Kobayashi N., Higashi T., Hara K., Shirataki H., and Matsuoka H. Effects of imidapril on NOS expression and myocardial remodelling in failing heart of Dahl salt-sensitive hypertensive rats. Cardiovasc Res 44 (1999) 518-526
37. Lee H.Y., Noh H.J., Gang J.G., et al. Inducible nitric oxide synthase (iNOS) expression is increased in lipopolysaccharide (LPS)-stimulated diabetic rat glomeruli: effect of ACE inhibitor and angiotensin II receptor blocker. Yonsei Med J 43 (2002) 183-192
38. Sorbi D., Fadly M., Hicks R., Alexander S., and Arbeit L. Captopril inhibits the 72 kDa and 92 kDa matrix metalloproteinases. Kidney Int 44 (1993) 1266-1272